-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

Benzinga·08/17/2026 16:24:15
Listen to the news
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.